Spain's Faes Farma has reported a 20% rise in profit in the first three months of 2008 compared to the year-before period, despite a 3.7% drop in sales due to the early Easter Holidays.
Income rose to 8.1 million euros ($12.5 million) during the quarter, whereas sales dropped to 50.2 million euros. However, the firm maintains this is due to the Easter Holidays being brought forward to March as it reports revenue for April showing an increase in spite of strong compulsory price restrictions.
The disparity between sales and profit is due to a 52% drop in costs for depreciation and amortization due to a redefinition of the useful life of some of the firm's oldest intangible assets, ie, trade marks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze